SANTIAGO, Chile, Dec. 19, 2024 / Andromeda Surgical, a pioneer in surgical robotics, has achieved a groundbreaking milestone with the announcement that Dr. Cristián Trucco from Universidad Católica de Chile has performed the world’s first robotic-assisted holmium laser enucleation of the prostate (HoLEP). This historic procedure, conducted via a tablet interface, marks the launch of Andromeda’s ASTRA clinical trial, a bold step towards transforming urological surgery worldwide.

Working alongside Dr. Rodrigo Ledezma of Universidad de Chile, Dr. Trucco will continue enrolling patients in the trial over the coming months. This achievement comes just 18 months after Andromeda Surgical’s founding in 2023, showcasing a rapid evolution from concept to clinical success.

Robotic-assisted HoLEP, branded as RoLEP™, is the first clinical application of Andromeda’s innovative platform. Originally developed in 1998 by Prof. Peter Gilling and Mr. Mark Fraundorfer in New Zealand, HoLEP has become the gold standard for treating benign prostatic hyperplasia (BPH). However, its steep learning curve has limited broader adoption.

Revolutionizing Urological Surgery
Andromeda’s mission is to streamline this learning curve, enabling urologists worldwide to perform HoLEP with the precision of top experts. "We are thrilled to be at the forefront of innovation in Chile and to participate in this trial led by Prof. Gilling," said Dr. Ledezma, co-principal investigator. "By integrating new technologies that offer navigational guidance, we aim to help urologists master the procedure more efficiently. Ultimately, this robotic system will expand access to HoLEP, benefiting countless BPH patients."

Prof. Gilling, a pioneer in the HoLEP technique, will serve as the lead principal investigator for the ASTRA study, with patient enrollment in New Zealand set to begin in early 2025.

The Future of Surgical Robotics
Andromeda’s endoscopic robotic platform seamlessly integrates with existing surgical tools, providing enhanced control and efficiency during transurethral procedures. The company plans to expand the system’s capabilities to address additional surgical indications and incorporate advanced levels of autonomy, further refining surgical outcomes and reducing learning curves.

"It’s incredibly rewarding to see our team’s hard work translate into real patient benefits," said Nick Damiano, CEO and co-founder of Andromeda Surgical. "This procedure not only represents the first robotic-assisted HoLEP in history but is also, to our knowledge, the first surgery performed using a tablet. This is a pivotal step in our mission to ensure that every patient has access to the best possible surgical outcomes every time."

About Andromeda Surgical
Based in South San Francisco, California, Andromeda Surgical develops autonomous surgical robots, with a focus on endourology procedures. The company’s vision is to simplify complex surgeries and empower surgeons to consistently deliver optimal patient outcomes. By combining expertise in medtech, autonomous systems, and AI, Andromeda collaborates with leading urologists worldwide to redefine surgical excellence.

For more information, visit: www.andromedasurgical.com